Ascletis Pharma's (HKG:1672) investigational new drug application for a phase I trial for ASC50 for the treatment of mild-to-moderate plaque psoriasis has been cleared by the US Food and Drug Administration (FDA), a Thursday Hong Kong bourse filing said.

The study will be conducted at multiple sites in the US, with dosing of patients with mild-to-moderate plaque psoriasis expected to start in the third quarter.